Alcon announces BRYTLY approval: Mizuho cuts target for Alcon stock

Published on 10/19/2026 at 09:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approval expands Alcon's eye-drop portfolio. Alcon stock costs EUR 59.03 on October 19, 2026; market value is USD 32.0 billion.

BRYTLY approval and earnings date

FDA approval for BRYTLY was announced on October 16, 2026.
Second-quarter revenue reached USD 2.82 billion against USD 2.77 billion consensus.
Alcon stock trades at EUR 59.03 at 9:38 a.m. CEST at Lang & Schwarz on October 19, 2026.
Third-quarter results are scheduled for November 10, 2026.

Financial editorial photography of glowing trading monitors. Screens display EYE CARE, OPHTHALMOLOGY sector data, SIX SWISS EXCHANGE text with upward trending candlestick charts, green on dark blue, shallow depth of field — Alcon CH0432492467: Handelsterminals zeigen EYE CARE, OPHTHALMOLOGY und SIX SWISS EXCHANGE mit steigenden Charts, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) was trading at EUR 59.03 at Lang & Schwarz on October 19, 2026 at 9:38 a.m. CEST. The company had announced U.S. Food and Drug Administration approval for BRYTLY redness-relief eye drops on October 16, 2026, according to Yahoo Finance.

BRYTLY adds a consumer option

BRYTLY is expected to reach major retailers and online stores in the coming months. The product is designed to reduce eye redness within one minute and provide results for up to 12 hours, while Alcon said it can last up to 50 percent longer than Lumify, according to the October 16 release carried by Yahoo Finance.

Three milestones shape the picture

Alcon's recent chronology links product development with commercial execution. On October 5, 2026, the company presented its UNITY platform, Clareon PanOptix Pro lenses and other products at the American Academy of Ophthalmology meeting, as reported by Alcon; on October 13, 2026, Mizuho cut its target from USD 85.00 to USD 80.00 while maintaining an Outperform rating, according to Markets Insider; and on October 16, 2026, Alcon announced the BRYTLY approval.

What does the launch mean for growth?

The operating backdrop was already expanding before BRYTLY. Alcon generated USD 2.82 billion of revenue in the second quarter of 2026, above the USD 2.77 billion consensus estimate, while adjusted earnings per share reached USD 0.84 versus USD 0.77 expected, according to Earnings Today. The new product therefore adds a consumer-facing launch to a business already spanning Surgical and Vision Care.

Results date and stock context

The next dated catalyst is Alcon's third-quarter 2026 results on November 10, 2026, listed in the earnings calendar of Yahoo Finance. The estimate shown there is USD 0.89 for earnings per share, giving investors a concrete benchmark for the next report.

Alcon stock holds a dated market value

Alcon's market capitalization was USD 32.0 billion as of October 16, 2026, and the company is listed on SIX and the NYSE under ticker ALC. Its eye care portfolio reaches more than 260 million people in over 140 countries and territories each year, according to the company release carried by Yahoo Finance. Alcon was trading at EUR 59.03 at Lang & Schwarz on October 19, 2026 at 9:38 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Alcon stock.